Seqirus Ships 2017-2018 Influenza Vaccinations

This article originally appeared here.
Share this content:
Trivalent and quadrivalent formulations of the influenza vaccine have begun shipping to US markets.
Trivalent and quadrivalent formulations of the influenza vaccine have begun shipping to US markets.

Seqirus announced it has begun shipping seasonal influenza vaccines for the upcoming 2017/18 flu season.

Seqirus will be offering both trivalent and quadrivalent formulations of the influenza vaccine, which were developed using egg- and cell-based technologies. In addition, Fluad™ (influenza vaccine, adjuvanted) will be available for patients aged ≥65 years, as well as Flucelvax Quadrivalent® (influenza vaccine) for patients aged ≥4 years.

Specific vaccines in the Seqirus portfolio for the upcoming flu season include Afluria Quadrivalent® (ages ≥18 years), the egg-based quadrivalent influenza vaccine, and Afluria® (ages ≥5 years) and Fluvirin® (ages ≥4 years), the egg-based trivalent influenza vaccines. 

Rapivab® (peramivir injection) is also available as a 1-dose intravenous (IV) antiviral treatment for acute influenza in patients aged ≥18 years.

Seqirus vaccines are supplied as prefilled syringes as well as multi-dose vials. A needle-free injection option is also provided for Afluria and Afluria Quadrivalent.

Reference

Seqirus begins shipping 2017-2018 influenza vaccines to the U.S. market [news release]. Summit, NJ: Seqirus Inc. http://www.seqirus.com/newsroom/Seqirus-Begins-Shipping-2017-2018-Influenza-Vaccines-to-the-US-Market. Published July 20, 2017. Accessed August 17, 2017. 

Sign Up for Free e-newsletters